USPTO Examiner SHIN DANA H - Art Unit 1635

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18661339METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHYMay 2024October 2024Abandon510NoNo
18408093MICRORNA-BASED PARTICLE FOR THE TREATMENT OF DYSREGULATED IMMUNE RESPONSEJanuary 2024December 2024Abandon1111NoNo
18482628Compositions and Methods for Treatment of Ocular Disease Associated with AngiogenesisOctober 2023December 2025Abandon2610NoNo
18481393GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USEOctober 2023November 2024Allow1321YesNo
18464200CIRCULAR RNAS AND PREPARATION METHODS THEREOFSeptember 2023October 2024Allow1411YesNo
18362698RNA EDITING VIA RECRUITMENT OF SPLICEOSOME COMPONENTSJuly 2023September 2024Allow1421YesNo
18224017TREATMENTS FOR OCULAR SURFACE DISORDERSJuly 2023February 2026Allow3131YesYes
18296596POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASEApril 2023October 2025Abandon3110NoNo
18186943METHODS AND COMPOSITIONS FOR TREATING LIPOPROTEIN-RELATED DISEASESMarch 2023January 2025Abandon2230YesNo
18177446POLYNUCLEOTIDES ENCODING A HUMAN FKRP PROTEINMarch 2023January 2026Allow3421NoNo
18041613PLASMID VECTORS AND NANOPARTICLES FOR TREATING OCULAR DISORDERSFebruary 2023March 2026Abandon3701NoNo
18167614ENGINEERED OXALATE DECARBOXYLASESFebruary 2023March 2026Abandon3701NoNo
18159161METHODS FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASEJanuary 2023March 2026Abandon3710NoNo
18145784VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA ADecember 2022October 2025Abandon3410NoNo
18082654OLIGONUCLEOTIDES FOR MLH1 MODULATIONDecember 2022February 2026Abandon3801NoNo
18078031SIGNAL BOOST CASCADE ASSAYDecember 2022September 2024Abandon2141YesNo
18063582NANOPARTICLE IMMUNOGENIC COMPOSITIONS AND VACCINATION METHODSDecember 2022February 2026Abandon3831NoYes
18058000PARTICLE-BASED ISOLATION OF PROTEINS AND OTHER ANALYTESNovember 2022January 2026Allow4921YesYes
17926678VLP FOR THE TREATMENT OF LEUKODYSTROPHIESNovember 2022February 2026Abandon3901NoNo
17989941POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASENovember 2022January 2026Abandon3811NoNo
17926564METHODS AND COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONSNovember 2022March 2026Abandon4001NoNo
17998371COMPOSITIONS USEFUL FOR TREATMENT OF POMPE DISEASENovember 2022February 2026Abandon3910NoNo
17984846TRANS-SPLICING RNA (tsRNA)November 2022March 2026Abandon4001NoNo
17978030METHODS OF DOSING CIRCULAR POLYRIBONUCLEOTIDESOctober 2022February 2024Abandon1620YesNo
17906175DIAGNOSTIC METHODS USING SIRT1 EXPRESSIONSeptember 2022January 2026Abandon4001NoNo
17822854Nucleic Acid Compounds for Binding to Complement Component 3 ProteinAugust 2022June 2025Abandon3401NoNo
17883452METHODS FOR TREATING PATIENTS HAVING SINUSOIDAL OBSTRUCTION SYNDROMEAugust 2022July 2025Abandon3511NoNo
17814860PLATELETS TRANSFECTED BY EXOGENOUS GENETIC MATERIAL AND PLATELET MICROPARTICLES OBTAINED BY SAID TRANSFECTED PLATELETS, METHOD FOR THE PREPARATION AND USES THEREOFAugust 2022March 2026Abandon4320NoNo
17814845PLATELETS TRANSFECTED BY EXOGENOUS GENETIC MATERIAL AND PLATELET MICROPARTICLES OBTAINED BY SAID TRANSFECTED PLATELETS, METHOD FOR THE PREPARATION AND USES THEREOFJuly 2022February 2026Abandon4320NoNo
17814647Compositions for treatment of polycystic kidney diseaseJuly 2022May 2025Abandon3410NoNo
17814781METHODS AND MEANS FOR EFFICIENT DKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-MRNAJuly 2022March 2025Abandon3201NoNo
17814328METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASEJuly 2022May 2025Abandon3310NoNo
17843848TARGETING MICRORNA FOR CANCER TREATMENTJune 2022July 2025Abandon3721NoNo
17841185PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERSJune 2022February 2025Allow3210NoNo
17805402EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHYJune 2022February 2025Abandon3210NoNo
17826946Use of Thermostable RNA Polymerases to Produce RNAs Having Reduced ImmunogenicityMay 2022August 2025Abandon3821NoNo
17825384EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCERMay 2022August 2025Abandon3821NoNo
17778380COMPOUNDS AND METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHYMay 2022January 2026Abandon4401NoNo
17726068COMPOSITIONS AND METHODS FOR EDITING THE ANGIOPOIETIN-LIKE 4 (ANGPTL4) GENEApril 2022December 2025Abandon4421NoYes
17708799COMPOSITIONS AND METHODS FOR TREATING SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY (SSADHD)March 2022March 2025Abandon3611NoNo
17765116TREATMENT OF SPINAL AND BULBAR MUSCULAR ATROPHYMarch 2022February 2025Allow3531NoNo
17763662METHOD FOR TREATING MOOD DISORDERSMarch 2022December 2025Abandon4501NoNo
17703334Compositions and Methods for MYC Messenger RNA InhibitorsMarch 2022August 2025Abandon4121NoNo
17698829CORONAVIRUS VACCINEMarch 2022July 2023Allow1621YesNo
17696808Combination Therapy for Treating Disorders of the EarMarch 2022January 2026Abandon4621NoNo
17591133HETERO DOUBLE-STRANDED antimiRFebruary 2022February 2025Abandon3610NoNo
17626324METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHYJanuary 2022September 2025Abandon4420YesNo
17571893RNA FOR CANCER THERAPYJanuary 2022December 2024Abandon3510NoNo
17563686COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING VIRAL INFECTIONSDecember 2021November 2023Abandon2321NoNo
17618776ENDONUCLEASE-RESISTANT MESSENGER RNA AND USES THEREOFDecember 2021June 2025Abandon4221NoNo
17549098SPLICE MODULATING OLIGONUCLEOTIDES AND METHODS OF USE THEREOFDecember 2021December 2024Abandon3601NoNo
17547791TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNFDecember 2021March 2025Abandon3911NoNo
17547232PREDICTIVE METHOD FOR ASSESSING THE SUCCESS OF EMBRYO IMPLANTATIONDecember 2021July 2024Abandon3111NoNo
17524876MEANS AND METHODS FOR REDUCING TUMORIGENICITY OF CANCER STEM CELLSNovember 2021April 2025Abandon4120NoNo
17610050COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEUKODYSTROPHY AND WHOLE ANIMAL AND CELLULAR MODELS FOR IDENTIFYING EFFICACIOUS AGENTS FOR TREATMENT OF THE SAMENovember 2021February 2026Abandon5121NoNo
17518704METHODS AND COMPOSITIONS USEFUL FOR NUCLEIC ACID ANALYSISNovember 2021May 2025Abandon4231NoNo
17516543COMBINATION THERAPYNovember 2021August 2025Abandon4520NoNo
17507669ANDROGEN RECEPTOR NUCLEIC ACIDS AND USES THEREOFOctober 2021January 2025Abandon3911NoNo
17506327METHODS FOR IMPROVING HUMAN EGG QUALITY USING MICRORNAsOctober 2021June 2024Abandon3120NoNo
17481670U1 snRNP Regulates Gene Expression and Modulates OncogenicitySeptember 2021September 2025Allow4840NoNo
17477327METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORSSeptember 2021September 2024Abandon3611NoNo
17438903OLIGONUCLEOTIDE HAVING ANTI-INFLAMMATORY ACTIVITYSeptember 2021November 2025Abandon5011NoNo
17405199COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOFAugust 2021April 2024Abandon3201NoNo
17401389Aptamers Against Clostridium DifficileAugust 2021June 2024Abandon3411NoNo
17397652MODULATION OF TRANSTHYRETIN EXPRESSIONAugust 2021August 2025Abandon4821NoNo
17391125METHODS OF TREATING MOTOR NEURON DISEASESAugust 2021May 2024Abandon3401NoNo
17389878Anti-Fibrinogen AptamersJuly 2021January 2025Allow4121NoNo
17386127Method of Treating Hepatic SteatosisJuly 2021April 2025Abandon4521NoNo
17385767METHOD FOR DIAGNOSIS AND PROGNOSIS OF CHRONIC HEART FAILUREJuly 2021February 2025Abandon4330NoNo
17371765METHOD FOR PREVENTING ORAL CANCERJuly 2021September 2024Abandon3811NoNo
17350004INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOFJune 2021March 2024Abandon3301NoNo
17346369METHODS AND COMPOSITIONS FOR TREATMENT OF FRONTOTEMPORAL DEMENTIAJune 2021October 2023Abandon2821NoNo
17342112BIOMARKERS FOR EARLY EMBRYONIC VIABILITY AND METHODS THEREOFJune 2021September 2024Abandon3911NoNo
17336112METHOD FOR SCREENING APTAMER BY USING MICROARRAY MICROFLUIDIC CHIPJune 2021October 2025Abandon5301NoNo
17331012UNIMOLECULAR NANOPARTICLES FOR EFFICIENT DELIVERY OF THERAPEUTIC RNAMay 2021March 2024Abandon3401NoNo
17292075METHOD FOR REDUCING THE RISK OF A CARDIOVASCULAR EVENT WITH CONJUGATED ANTISENSE COMPOUNDS TARGETING APO(A)May 2021November 2024Abandon4210NoNo
17307350SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDESMay 2021July 2024Abandon3911NoNo
17289953Genome Editing by Guided Endonuclease and Single-stranded OligonucleotideApril 2021April 2025Abandon4710NoNo
17241001COMBINATION THERAPIES FOR INNER EAR SENSORY HAIR CELL REGENERATION/REPLACEMENTApril 2021October 2025Abandon5430YesYes
17234541EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHYApril 2021January 2024Abandon3310NoNo
17231896SPHERICAL NUCLEIC ACID TLR9 AGONISTSApril 2021January 2024Abandon3310NoNo
17228994Aptamers Against Clostridium DifficileApril 2021April 2025Allow4831YesNo
17284556Nucleic Acid Compounds for Binding Immunoglobulin GApril 2021September 2024Abandon4121NoNo
17283941tRNA-DERIVED FRAGMENTS AS BIOMARKERS FOR PARKINSON'S DISEASEApril 2021May 2025Abandon4911NoNo
17225823COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITYApril 2021November 2024Allow4321YesNo
17221457SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONSApril 2021December 2023Abandon3310NoNo
17183205COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR VFebruary 2021November 2023Abandon3201NoNo
17163168METHODS AND COMPOSITIONS FOR NUCLEIC ACID EXPRESSION INVOLVING INHIBITION of NF-kB PATHWAYS AND/OR IRF PATHWAYSJanuary 2021December 2024Abandon4731NoNo
17157565METHODS FOR IDENTIFYING THERAPEUTIC TARGETS AND TREATING AND MONITORING CANCERSJanuary 2021October 2024Allow4531NoNo
17157131Methods of Manipulating the Fate of CellsJanuary 2021November 2023Abandon3401NoNo
17154280KIT FOR AFLATOXIN B1 (AFB1) MONITORINGJanuary 2021August 2023Allow3120NoNo
17154325POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2January 2021October 2024Allow4522NoNo
17153067AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJanuary 2021September 2023Abandon3201NoNo
17153215AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJanuary 2021September 2023Allow3201NoNo
17130716EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHYDecember 2020November 2023Allow3420NoNo
17129761SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFDecember 2020April 2023Abandon2801NoNo
17129117METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53December 2020October 2024Abandon4620NoYes
17129311METHODS FOR IDENTIFYING THERAPEUTIC AGENTS WHICH INTERACT WITH STK24December 2020June 2025Abandon5341YesNo
17127866COMPOUNDS AND METHODS FOR MODULATION OF SMN2December 2020November 2022Abandon2301NoNo
17251558PHARMACEUTICAL COMPOSITION COMPRISING FUSION PROTEIN OF CELL-PENETRATING PEPTIDE AND RPE65 FOR TREATMENT OF LEBER'S CONGENITAL AMAUROSISDecember 2020May 2024Abandon4110NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHIN, DANA H.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
23
Examiner Affirmed
16
(69.6%)
Examiner Reversed
7
(30.4%)
Reversal Percentile
47.1%
Lower than average

What This Means

With a 30.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
147
Allowed After Appeal Filing
17
(11.6%)
Not Allowed After Appeal Filing
130
(88.4%)
Filing Benefit Percentile
14.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 11.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SHIN, DANA H - Prosecution Strategy Guide

Executive Summary

Examiner SHIN, DANA H works in Art Unit 1635 and has examined 925 patent applications in our dataset. With an allowance rate of 23.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner SHIN, DANA H's allowance rate of 23.0% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SHIN, DANA H receive 2.56 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SHIN, DANA H is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +35.9% benefit to allowance rate for applications examined by SHIN, DANA H. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 8.5% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 24.2% of cases where such amendments are filed. This entry rate is in the 32% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 31.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 32% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 62.3% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 71.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 90.6% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.7% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.